Page last updated: 2024-08-23

pravastatin and Kidney Failure

pravastatin has been researched along with Kidney Failure in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (12.50)	18.2507
2000's	6 (75.00)	29.6817
2010's	1 (12.50)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Akishita, M; Iijima, K; Ito, Y; Ouchi, Y; Son, BK	1
Iwasaka, T; Kamihata, H; Manabe, K; Motohiro, M; Nakamura, S; Senoo, T; Sugiura, T; Yoshida, S	1
Quiroz, Y; Rodríguez-Iturbe, B; Sato, T; Vaziri, ND	1
Bouchier-Hayes, D; Casey, RG; Chen, G; Joyce, M; Roche-Nagle, G	1
Cobbe, SM; Craven, T; Curhan, GC; Furberg, C; Isles, C; Packard, C; Pfeffer, MA; Sacks, FM; Shepherd, J; Simes, J; Tonelli, M; Tonkin, A; West, M	1
Ito, MK; Lin, JC	1
Braunwald, E; Byington, RP; Cobbe, SM; Davis, BR; Friedman, CP; Keech, A; Pfeffer, MA; Sacks, FM; Tonkin, A	1

Reviews

1 review(s) available for pravastatin and Kidney Failure

Article	Year
Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation, 2005, Jul-12, Volume: 112, Issue:2 Topics: Aged; Chronic Disease; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Models, Statistical; Pravastatin; Randomized Controlled Trials as Topic; Renal Insufficiency; Retrospective Studies; Risk	2005

Article

Year

Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease.

Circulation, 2005, Jul-12, Volume: 112, Issue:2

Topics: Aged; Chronic Disease; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Models, Statistical; Pravastatin; Randomized Controlled Trials as Topic; Renal Insufficiency; Retrospective Studies; Risk

2005

Other Studies

7 other study(ies) available for pravastatin and Kidney Failure

Article	Year
Pravastatin and olmesartan synergistically ameliorate renal failure-induced vascular calcification. Journal of atherosclerosis and thrombosis, 2014, Volume: 21, Issue:9 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Blood Pressure; Calcinosis; Drug Synergism; Drug Therapy, Combination; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Male; Pravastatin; Rats; Rats, Wistar; Renal Insufficiency; Tetrazoles	2014
Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency. Journal of cardiology, 2009, Volume: 54, Issue:2 Topics: Aged; Angioplasty; Biomarkers; Cardiovascular Diseases; Contrast Media; Coronary Angiography; Creatinine; Diabetes Mellitus; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Logistic Models; Male; Middle Aged; Pravastatin; Renal Insufficiency; Risk Factors	2009
AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia, and glomerulosclerosis in the Imai rat. Kidney international, 2004, Volume: 66, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cholesterol, VLDL; Drug Therapy, Combination; Glomerulosclerosis, Focal Segmental; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Imidazoles; Male; Olmesartan Medoxomil; Pravastatin; Proteinuria; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Renal Insufficiency; Tetrazoles; Triglycerides	2004
Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease. The Journal of surgical research, 2005, Volume: 123, Issue:2 Topics: Animals; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Glomerular Filtration Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pravastatin; Proteinuria; Rats; Rats, Sprague-Dawley; Renal Circulation; Renal Insufficiency; Triglycerides; Urine	2005
Chronic creatine kinase elevation not associated with HMG-CoA reductase inhibitor treatment. The Annals of pharmacotherapy, 1999, Volume: 33, Issue:2 Topics: Biomarkers, Tumor; Creatine Kinase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prostatic Neoplasms; Renal Insufficiency	1999
Transplanted livers and kidneys for HIV+ people. TreatmentUpdate, 2001,Spring, Volume: 12, Issue:12 Topics: Antiretroviral Therapy, Highly Active; Cyclosporine; Hepatitis B; Hepatitis C; HIV Infections; Humans; Hypolipidemic Agents; Kidney Transplantation; Liver Failure; Liver Transplantation; Lovastatin; Pravastatin; Renal Insufficiency; San Francisco	2001
Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation, 2002, May-21, Volume: 105, Issue:20 Topics: Aged; Anticholesteremic Agents; Breast Neoplasms; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Cohort Studies; Comorbidity; Demography; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Liver Diseases; Male; Middle Aged; Multivariate Analysis; Muscular Diseases; Pravastatin; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Renal Insufficiency; Risk; Risk Assessment; Time	2002